Loading
A phase 2 trial of Zamtocabtagene autoleucel, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Miltenyi Biomedicine GmbH, now recruiting.
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients is a phase 2 interventional study registered as NCT04844866 by Miltenyi Biomedicine GmbH, with 213 participants planned, started 2021-08-18 and due to reach its primary completion in 2025-01-15. Interventions recorded: MB-CART2019.1, Standard of Care. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Miltenyi Biomedicine, Zamtocabtagene autoleucel, Diffuse large B-cell lymphoma.
Shares Miltenyi Biomedicine, Zamtocabtagene autoleucel, Bendamustine, Diffuse large B-cell lymphoma.
Shares Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
Shares CAPOX (capecitabine, oxaliplatin), Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
Shares CAPOX (capecitabine, oxaliplatin), Gemcitabine, Diffuse large B-cell lymphoma.
Shares Bendamustine, Rituximab, Diffuse large B-cell lymphoma.
Shares CAPOX (capecitabine, oxaliplatin), Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/